A Barrier for Lobbyists
National Drug Formulary consisting of 700 international non-proprietary names of pharmaceutical drugs and about three thousand trade names has been established in Kazakhstan.
According to Gulzira Zhusupova, acting director of Medicinal Center RESP, Healthcare Development Center of MoH&SD RK, this formulary includes established global products with evidenced clinical efficacy and safety. The maximum procurement prices for healthcare organizations for these drugs are to be defined.
Scientists from Kazakhstan are already training to work with formulary. They will be obliged to prescribe drugs in national formulary to their patients. It will prevent lobbying the interests of Pharma companies. Patients will also be able to see the list of approved drugs at the special internet-resource where product names are specified with information on their properties and side effects.
Kazakhstan national drug formulary is the first and only in CIS. In future pediatric and dental lists are expected to be developed.